What is Seraxis?
Founded in 2013, Seraxis operates at the intersection of biotechnology and endocrinology. The company has developed a proprietary cell line capable of manufacturing transplant-ready pancreatic islets, a critical component for restoring insulin production in patients with diabetes. Complementing this biological innovation is SeraGraft, a specialized device engineered to shield these human pancreas cells from immune system rejection. This dual-pronged approach addresses the primary hurdles in islet transplantation, positioning Seraxis as a pivotal player in the pursuit of a functional cure for insulin-dependent conditions. The company's operational focus remains on scaling these manufacturing processes to meet the rigorous demands of clinical application and regulatory approval.
How much funding has Seraxis raised?
Seraxis has raised a total of $40.1M across 2 funding rounds:
Debt
$87K
Series C
$40M
Debt (2021): $87K with participation from PPP
Series C (2021): $40M led by Polaris Partners, JDRF T1D Fund, Frazier Healthcare Partners, and Eli Lilly and Company
Key Investors in Seraxis
Polaris Partners
A venture capital firm specializing in backing transformational companies within the biotech and healthcare sectors, providing deep operational expertise and strategic guidance.
JDRF T1D Fund
A venture impact fund dedicated to accelerating treatments and cures for Type 1 Diabetes by strategically investing in innovative therapies and disease-modifying technologies.
Eli Lilly and Company
A global biopharmaceutical leader focused on the discovery and commercialization of prescription medicines, with a long-standing commitment to advancing diabetes care and research.
What's next for Seraxis?
With the recent influx of capital, Seraxis is well-positioned to advance its core therapeutic candidates through the next phases of clinical validation. The strategic focus will likely shift toward optimizing the manufacturing scalability of its pancreatic islets and refining the performance of the SeraGraft delivery system. As the company transitions from development to more advanced clinical stages, the emphasis will remain on demonstrating long-term efficacy and safety in human trials. Continued collaboration with specialized healthcare investors will be instrumental in navigating the complex regulatory environment and establishing a robust commercialization strategy for their innovative diabetes treatment solutions.
See full Seraxis company page
